<DOC>
	<DOCNO>NCT00417963</DOCNO>
	<brief_summary>To evaluate safety efficacy Bard ViVEXX Carotid Stent Emboshield BareWire Rapid Exchange Embolic Protection System treatment extracranial carotid artery stenosis patient high risk carotid endarterectomy .</brief_summary>
	<brief_title>ViVEXX Carotid Revascularization Trial ( VIVA )</brief_title>
	<detailed_description>Patients clinically significant stenosis within common and/or internal carotid artery high risk carotid endarterectomy amenable percutaneous treatment include embolic protection , balloon angioplasty carotid stent placement .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<criteria>The patient symptomatic asymptomatic carotid artery stenosis meet one follow criterion : Symptomatic : &gt; = 50 % carotid stenosis angiography history nondisabling stroke , transient ischemic attack ( TIA ) hemisphere supply target vessel within 180 day procedure . Asymptomatic : &gt; = 80 % carotid stenosis angiography without neurological symptom . High risk carotid endarterectomy : anatomical comorbid . History symptom stroke TIA within 24 hour procedure Extensive diffuse atherosclerotic disease Severe vascular tortuosity anatomy would preclude safe introduction device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Carotid</keyword>
	<keyword>Artery</keyword>
	<keyword>Stenosis</keyword>
</DOC>